중증하지허혈 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 방법별(약제, 의료기기), 지역별, 경쟁 구도(2020-2030년)

Global Critical Limb Ischemia Treatment Market was valued at USD 4.29 Billion in 2024 and is anticipated to reach USD 6.36 Billion in the forecast period with a CAGR of 6.75% through 2030. The market is poised for significant growth due to a confluence of factors such as the rising prevalence of chronic diseases, particularly diabetes, and the increasing focus on advancing treatment options for limb ischemia. The expanding global diabetic population is a primary contributor to the surge in CLI cases, as diabetes often leads to peripheral arterial disease (PAD), a major cause of CLI. As more individuals with PAD progress to CLI, the demand for effective and innovative treatment solutions is accelerating. This trend is driving the growth of minimally invasive and surgical treatment options, as well as therapies aimed at improving blood flow to the affected areas.

Technological advancements are transforming the CLI treatment landscape, with key innovations in endovascular procedures and regenerative medicine opening new avenues for care. Endovascular revascularization techniques, such as angioplasty and stenting, are gaining popularity due to their ability to offer safer and quicker recovery times compared to traditional surgical methods. Furthermore, the emergence of stem cell therapy and gene therapy as potential treatments is creating exciting opportunities for the market. These innovative therapies aim to restore blood flow and promote tissue regeneration, offering promising solutions to patients who are not responsive to conventional treatments. As the industry embraces these new technologies, healthcare providers are increasingly able to offer patients more personalized and effective treatments, improving both outcomes and quality of life.

The CLI treatment market faces a number of challenges that may impact its growth trajectory. One of the key obstacles is the lack of awareness and timely diagnosis, as many patients do not seek treatment until the condition has reached a critical stage. This delay in intervention often complicates treatment options, leading to more advanced and costly care. Furthermore, the high cost of advanced treatments and the limited access to cutting-edge healthcare facilities in underserved regions may restrict the market's expansion. Despite these challenges, the growing emphasis on early diagnosis, coupled with advancements in healthcare infrastructure, is expected to drive further market growth. The combination of increasing awareness, technological innovation, and demand for effective treatment solutions presents a promising outlook for the global Critical Limb Ischemia Treatment Market during the forecast period.

Key Market Drivers

Aging Population and Increasing Disease Prevalence

The Global Critical Limb Ischemia Treatment Market is experiencing significant growth, driven by the confluence of an aging population and the increasing prevalence of vascular diseases. CLI, characterized by severe obstruction of blood flow to the extremities, often results in debilitating conditions and, in severe cases, limb loss. The aging demographic is inherently more susceptible to vascular complications, thereby intensifying the demand for effective CLI treatments. In the United States, the older population increased by 50.9 million, from 4.9 million (4.7% of the total U.S. population) in 1920 to 55.8 million (16.8%) in 2020.

Simultaneously, the escalating prevalence of diseases associated with vascular complications, such as diabetes and hypertension, amplifies the CLI burden globally. These chronic conditions significantly elevate the risk of developing critical limb ischemia, driving a parallel surge in the demand for advanced treatment modalities. The Global Burden of Disease study reported that 202 million adults worldwide have peripheral artery disease (PAD), a higher prevalence than ischemic heart disease (154 million), heart failure (64 million), Alzheimer's disease (44 million), cancer (43 million), HIV/AIDS (36 million), and opioid addiction (27 million).

In response to this dual demographic and disease-driven demand surge, there has been a proliferation of innovative therapeutic interventions and technological advancements. Companies operating in the global CLI treatment market are strategically positioning themselves to capitalize on this burgeoning demand, fostering a competitive landscape focused on research, development, and commercialization of cutting-edge solutions. The symbiotic relationship between an aging population and escalating disease prevalence is fueling the growth trajectory of the Global Critical Limb Ischemia Treatment Market.

Technological Advancements in Endovascular Therapies

The Global Critical Limb Ischemia Treatment Market is experiencing significant growth, driven by technological advancements in endovascular therapies. Innovations in minimally invasive procedures, such as endovascular revascularization, have revolutionized the treatment landscape for critical limb ischemia. These advancements enable physicians to navigate and treat vascular obstructions with increased precision, reduced invasiveness, and enhanced patient outcomes. The integration of cutting-edge technologies, such as advanced imaging modalities and catheter-based interventions, allows for more accurate diagnosis and targeted treatment of critical limb ischemia. These technological breakthroughs not only streamline the therapeutic process but also contribute to shorter recovery times and improved overall patient experiences. Continuous research and development efforts by industry players to enhance endovascular devices, stents, and drug-eluting technologies are fostering a dynamic market ecosystem. The market's response to these innovations is evident in the growing adoption of endovascular therapies as preferred methods for CLI treatment.

A study published in the Journal of Vascular Surgery in 2023 highlighted that endovascular interventions have become the preferred approach for patients with chronic limb-threatening ischemia (CLTI), with a higher proportion of endovascular interventions in the U.S. (75.9% vs. 69.2%) compared to Canada. This trend underscores the increasing preference for minimally invasive procedures over traditional surgical methods. Furthermore, the development of novel endovascular technologies, such as intravascular lithotripsy and the Tack endovascular stent, has expanded treatment options for CLI patients, particularly those with complex arterial lesions.

Increasing Awareness and Early Diagnosis

The growth of the Global Critical Limb Ischemia (CLI) Treatment Market is significantly propelled by a dual synergy of increasing awareness and early diagnosis initiatives. Heightened awareness campaigns, both among healthcare professionals and the general population, have played a pivotal role in educating about the risks and symptoms associated with critical limb ischemia. This has led to a proactive approach towards seeking medical attention for potential vascular issues.

Early diagnosis, facilitated by improved medical education and accessible diagnostic technologies, ensures timely intervention and a more effective treatment trajectory. As individuals and healthcare providers become more attuned to recognizing early signs of critical limb ischemia, there is a growing emphasis on preventive measures and the adoption of prompt therapeutic interventions. Early detection not only improves patient outcomes but also reduces the overall economic burden associated with advanced and complex treatments. In response to this paradigm shift, the Global CLI Treatment Market is witnessing increased demand for preventive and curative solutions, driving research, development, and market penetration. The collaborative impact of heightened awareness and early diagnosis is reshaping the treatment landscape, fostering a dynamic market environment focused on proactive vascular health management and fueling the market's sustained growth.

Key Market Challenges

High Treatment Costs

The growth of the Global Critical Limb Ischemia (CLI) Treatment Market faces a notable obstacle in the form of high treatment costs. The complex nature of critical limb ischemia necessitates advanced medical interventions, often involving sophisticated procedures, cutting-edge technologies, and specialized healthcare professionals. As a result, the overall cost of diagnosis, treatment, and post-treatment care escalates significantly.

This high cost of CLI treatment poses a barrier for patients seeking timely and effective medical intervention. The financial burden on individuals, combined with potential limitations in insurance coverage, may deter patients from pursuing necessary treatments. Moreover, the economic strain extends to healthcare systems, influencing resource allocation and budget considerations. The market's growth is impeded as the high treatment costs contribute to disparities in access to critical limb ischemia care, limiting the market's reach and adoption. Industry stakeholders are increasingly pressured to address these cost challenges through innovations that enhance treatment efficiency, reduce hospitalization durations, and optimize resource utilization. Efforts to make advanced treatments more cost-effective are essential for overcoming this barrier and ensuring broader accessibility, ultimately fostering the sustainable growth of the Global Critical Limb Ischemia Treatment Market.

Complexity of Disease Management

The complexity of disease management poses a significant impediment to the growth of the Global Critical Limb Ischemia (CLI) Treatment Market. Critical limb ischemia is a multifaceted vascular disorder that often requires a comprehensive and intricate approach to diagnosis and treatment. The diverse range of patient presentations, varying degrees of disease severity, and associated comorbidities add layers of complexity to the management of CLI.

This complexity results in challenges for healthcare providers in developing standardized and universally applicable treatment protocols. Tailoring interventions to individual patient needs demands a nuanced understanding of the disease, and the variability in responses further complicates the establishment of a one-size-fits-all solution. Additionally, the intricate nature of critical limb ischemia management may necessitate a multidisciplinary healthcare team, driving up operational and coordination costs. The intricacies in disease management also impact research and development efforts, as creating universally effective therapeutic interventions becomes a formidable task. Overcoming these complexities requires concerted efforts in collaborative research, the development of personalized medicine approaches, and advancements in diagnostic tools. Addressing the challenges posed by the complexity of critical limb ischemia management is crucial for unlocking the full potential of the market and facilitating its sustained growth.

Key Market Trends

Rise of Cell and Gene Therapies

The Global Critical Limb Ischemia (CLI) Treatment Market is experiencing significant growth, driven by the increasing prevalence of lifestyle-related diseases such as diabetes and hypertension, which are major contributors to peripheral arterial disease (PAD) and, consequently, CLI. According to the Cleveland Clinic, more than 10% of adults in the United States are affected by critical limb ischemia, with the condition leading to severe complications, including amputation and increased mortality rates.

In response to the escalating burden of CLI, there is a growing emphasis on developing advanced therapeutic interventions. Cell and gene therapies have emerged as promising modalities, offering potential for tissue regeneration and improved blood flow in ischemic limbs. A Phase 1 clinical trial published in Stem Cell Research & Therapy evaluated the safety and feasibility of using placenta-derived mesenchymal stem cells in patients with CLI, highlighting the potential of cell-based treatments in enhancing blood flow to ischemic areas.

Advancements in medical technologies are also propelling market growth. The U.S. Food and Drug Administration (FDA) has approved several innovative treatments for CLI, including the LimFlow System, which offers a minimally invasive approach to create an arterio-venous bypass graft in the below-the-knee vasculature. This device provides an alternative for patients who are not candidates for conventional revascularization procedures.

Focus on Patient-Centered Care

The growth of the Global Critical Limb Ischemia (CLI) Treatment Market is strongly influenced by the industry's increasing focus on patient-centered care. Recognizing the unique challenges faced by individuals with critical limb ischemia, healthcare providers and industry stakeholders are emphasizing personalized, patient-centric approaches to treatment. This shift involves tailoring medical interventions to accommodate the specific needs, preferences, and circumstances of patients, fostering a more holistic and empathetic healthcare experience.

Patient-centered care not only improves the overall quality of life for individuals with critical limb ischemia but also enhances treatment adherence and outcomes. It involves collaborative decision-making, clear communication, and a comprehensive understanding of the patient's lifestyle and aspirations. This approach resonates with a growing demand for more compassionate and individualized healthcare solutions. In the context of the CLI Treatment Market, a patient-centered focus is driving innovations in treatment protocols, device designs, and supportive care services. The integration of patient perspectives in the development and delivery of treatments is fostering a patient-friendly ecosystem that encourages better engagement and satisfaction. As healthcare providers increasingly prioritize the patient experience, this emphasis on patient-centered care is anticipated to be a key driver in the sustained growth of the Global Critical Limb Ischemia Treatment Market.

Segmental Insights

Treatment Insights

Based on the Treatment, Embolic Protection Devices emerged as the fastest growing segment in the Global Critical Limb Ischemia Treatment Market in 2024, reflecting their vital role in improving patient outcomes during vascular procedures. These devices are specifically designed to capture and remove embolic debris, which can dislodge during endovascular interventions like angioplasty and stenting, thereby preventing potential blockages in smaller distal arteries. Their use is particularly critical in treating CLI, where compromised blood flow already presents significant challenges to limb and overall patient health. The increasing adoption of minimally invasive endovascular procedures has driven the demand for embolic protection devices. As these procedures become the preferred treatment option for CLI patients, the need to mitigate procedural risks and improve long-term success rates is paramount. Studies, such as those cited by the National Library of Medicine, underscore the efficacy of embolic protection devices in reducing the incidence of distal embolization, which can otherwise lead to further ischemic complications. Moreover, advancements in device design and material have enhanced their usability and effectiveness, aligning with the broader trend of innovation in vascular intervention technologies. This segment's growth underscores its importance in addressing the complexities of CLI treatment, contributing to better clinical outcomes and patient quality of life.

Regional Insights

North America emerged as the dominant region in the Global Critical Limb Ischemia Treatment Market in 2024. This is owing to the region's robust healthcare infrastructure, high prevalence of peripheral arterial disease (PAD), and advanced treatment options. CLI which is a severe stage of PAD, is particularly prevalent among aging populations and individuals with diabetes and cardiovascular diseases, conditions that are widespread in North America. According to the Centers for Disease Control and Prevention (CDC), approximately 6.5 million Americans aged 40 and older suffer from PAD, underscoring the critical need for effective CLI treatments.

The dominance of North America is further fueled by strong investments in medical research and development, which have led to innovations in therapies and devices targeting CLI. Advanced treatments such as minimally invasive revascularization techniques, cell and gene therapies, and next-generation embolic protection devices are widely adopted in the region, driving market growth. Moreover, supportive regulatory frameworks from agencies like the U.S. Food and Drug Administration (FDA) accelerate the approval of novel therapies, ensuring timely access for patients. Additionally, public awareness initiatives and improved diagnostic capabilities contribute to earlier detection and treatment of CLI. With ongoing advancements and a focus on improving patient outcomes, North America continues to lead in shaping the future of CLI treatment.

Key Market Players

• Medtronic Plc
• LimFlow SA
• Cynata Therapeutics Ltd
• Cardiovascular Systems, Inc.
• Eli Lilly and Company
• Abbott Laboratories
• Rexgenero Ltd.
• Cesca Therapeutics (ThermoGenesis Holdings, Inc)
• Teva Pharmaceuticals
• Micro Medical Solutions
• Boston Scientific Corporation

Report Scope:

In this report, the Global Critical Limb Ischemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Critical Limb Ischemia Treatment Market, By Treatment:

• Drugs
  • Antiplatelet Drugs
  • Antihypertensive Agents
  • Lipid-lowering Agents
  • Antithrombotic Agents,
  • Others
• Devices
  • Embolic Protection Devices
  • Peripheral Dilatation System
  • Balloon Dilators
  • Vascular Stents

Critical Limb Ischemia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Critical Limb Ischemia Treatment Market.

Available Customizations:

Global Critical Limb Ischemia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Critical Limb Ischemia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Drugs, Devices)
    • 5.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 5.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 5.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.3. By Company (2024)
• 5.3. Market Map
• 5.3.1 By Treatment
• 5.3.2 By Region

6. North America Critical Limb Ischemia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Drugs, Devices)
    • 6.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 6.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Critical Limb Ischemia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
  • 6.3.2. Canada Critical Limb Ischemia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
  • 6.3.3. Mexico Critical Limb Ischemia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment

7. Europe Critical Limb Ischemia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Drugs, Devices)
    • 7.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 7.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Critical Limb Ischemia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
  • 7.3.2. Germany Critical Limb Ischemia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
  • 7.3.3. United Kingdom Critical Limb Ischemia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
  • 7.3.4. Italy Critical Limb Ischemia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
  • 7.3.5. Spain Critical Limb Ischemia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment

8. Asia-Pacific Critical Limb Ischemia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Drugs, Devices)
    • 8.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 8.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 8.2.2. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Critical Limb Ischemia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
  • 8.3.2. India Critical Limb Ischemia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
  • 8.3.3. Japan Critical Limb Ischemia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
  • 8.3.4. South Korea Critical Limb Ischemia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Critical Limb Ischemia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment

9. South America Critical Limb Ischemia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Drugs, Devices)
    • 9.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 9.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 9.2.2. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Critical Limb Ischemia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
  • 9.3.2. Argentina Critical Limb Ischemia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
  • 9.3.3. Colombia Critical Limb Ischemia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment

10. Middle East and Africa Critical Limb Ischemia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Drugs, Devices)
    • 10.2.1.1. By Drugs (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others)
    • 10.2.1.2. By Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)
  • 10.2.2. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Critical Limb Ischemia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
  • 10.3.2. Saudi Arabia Critical Limb Ischemia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
  • 10.3.3. UAE Critical Limb Ischemia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Critical Limb Ischemia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment s

15. Competitive Landscape

• 15.1. Medtronic plc
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. LimFlow SA
• 15.3. Cynata Therapeutics Ltd
• 15.4. Cardiovascular Systems, Inc.
• 15.5. Eli Lilly and Company
• 15.6. Abbott Laboratories
• 15.7. Rexgenero Ltd.
• 15.8. Cesca Therapeutics (ThermoGenesis Holdings, Inc)
• 15.9. Teva Pharmaceuticals
• 15.10. Micro Medical Solutions
• 15.11. Boston scientific corporation

16. Strategic Recommendations

17. About Us & Disclaimer